6533b873fe1ef96bd12d4e7c

RESEARCH PRODUCT

Naloxone increases the response of growth hormone and prolactin to stimuli in obese humans.

U. SchneiderJ. BeyerU. KrauseG. Plewe

subject

AdultMaleendocrine systemmedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and Metabolismmedicine.medical_treatment(+)-NaloxoneArginineGlucagonEndocrinologyAdrenocorticotropic HormoneDouble-Blind MethodInternal medicinemedicineHumansObesityOpioid peptideThyrotropin-Releasing HormoneTriiodothyroninebusiness.industryNaloxoneInsulinbeta-EndorphinAntagonistMiddle AgedProlactinProlactinEndocrinologyGrowth HormoneFemaleEndorphinsOpiatebusinesshormones hormone substitutes and hormone antagonists

description

Opiates stimulate the growth hormone and prolactin responses to stimuli in non-obese humans. Obese patients, however, show lowered growth hormone and prolactin responses and raised beta-endorphin levels. We therefore investigated the effect of the opiate antagonist naloxone on the stimulated growth hormone and prolactin secretions in a controlled double-blind study in obese patients. All patients received 200 micrograms TRH and 0.5 g/kg b.w. arginine together with 2 mg of naloxone or placebo i.v. in a randomized sequence. The TRH- and arginine-induced increases in prolactin and growth hormone were significantly greater after administration of naloxone (p less than 0.05). Naloxone also produced a significant increase in ACTH, cortisol and beta-endorphin when compared with placebo. TSH, triiodothyronine, thyroxine, insulin, glucagon and blood glucose showed no significant differences between both days of the trial. The effect of naloxone on growth hormone and prolactin secretions in obese humans can thus be regarded as a partial normalization. We therefore conclude that the hypothalamic regulatory disturbance of growth hormone and prolactin secretions in the obese could be caused by raised opiate levels.

10.1007/bf03347177https://pubmed.ncbi.nlm.nih.gov/3035002